Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.92 |
| ▸ | ATM | Q13315 | 1/20 | 0.92 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | KDM1A | O60341 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | FNTA | P49354 | 10/20 | 0.61 |
| ▸ | FNTB | P49356 | 10/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.57 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | SQLE | Q14534 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9475040 | 1.00 | KDM4E (0.92) | KDM4EATMKMT2AKDM1APOLB | |
| SCHEMBL7943006 | 1.00 | KDM4E (0.92) | KDM4EATMKMT2AKDM1APOLB | |
| SCHEMBL3088919 | 1.00 | KDM4E (0.92) | KDM4EATMKMT2AKDM1APOLB | |
| SCHEMBL10748886 | 1.00 | KDM4E (0.92) | KDM4EATMKMT2AKDM1APOLB | |
| SCHEMBL10566443 | 1.00 | KDM4E (0.92) | KDM4EATMKMT2AKDM1APOLB | |
| Geranylgeranoic Acid SCHEMBL10781543 | 1.00 | KDM4E (0.92) | KDM4EATMKMT2AKDM1APOLB | |
| Geranylgeranoic Acid SCHEMBL10405196 | 1.00 | KDM4E (0.92) | KDM4EATMKMT2AKDM1APOLB | |
| SCHEMBL1470207 | 1.00 | KDM4E (0.92) | KDM4EATMKMT2AKDM1APOLB | |
| SCHEMBL9366045 | 1.00 | KDM4E (0.92) | KDM4EATMKMT2AKDM1APOLB | |
| SCHEMBL7943004 | 1.00 | KDM4E (0.92) | KDM4EATMKMT2AKDM1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629268-B2 | Cyclisation process of forming a multiple ring compound | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-01-14 | — | — | US | disclosed |
| US-20130046090-A1 | CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2013-02-21 | — | — | US | disclosed |
| US-8227645-B2 | Cyclisation process of forming a multiple ring compound | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-07-24 | — | — | US | disclosed |
| US-20100228058-A1 | CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2010-09-09 | — | — | US | disclosed |
| US-4762829-A | ANTICOAGULANTS | EISAI CO., LTD. (JP) | 1988-08-09 | — | — | US | disclosed |
| US-4742058-A | AMIDES, ANTICOAGULANTS | EISAI CO., LTD. (JP) | 1988-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100228058-A1 | CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND | DHPS, GGPS1, COASY | KDM4E 2747/4885ATM 1393/4885KMT2A 2281/4885 |
| US-20130046090-A1 | CYCLISATION PROCESS OF FORMING A MULTIPLE RING COMPOUND | COASY, AKR1C4, AKR1C2 | KDM4E 3322/4885ATM 808/4885KMT2A 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.